Additional file 1 of TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro

Additional file 1: Table S1-S11. Table S1. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) checklist. Table S2. The details of eQTL used in the study. Table S3. Primers used in qPCR experiments. Table S4. Mendelian Randomization Analysis Results for Blood Gene Expression and ALS Outcomes of SNPs under different criteria. Table S5. Mendelian Randomization Analysis Results for Brain Gene Expression and ALS Outcomes of SNPs under different criteria. Table S6. Mendelian Randomization Analysis Results for Spinal cord Gene Expression and ALS Outcomes of SNPs under different criteria. Table S7. Druggable genes associated with ALS. Table S8. Sensitivity analyses by MR-Egger and weighted median methods. Table S9. The results of colocalization analysis. Table S10. Wald ratio approach supporting the expression of druggable genes significantly associated with ALS risk. Table S11. The phenome-wide MR results of blood TBK1 in IVW or Wald ratio method.附加文件1：表S1至S11。表S1：《利用孟德尔随机化加强流行病学观察性研究报告规范》（STROBE-MR）核查清单。表S2：本研究中使用的表达数量性状基因座（eQTL）详情。表S3：定量聚合酶链反应（qPCR）实验所用引物。表S4：不同筛选标准下，血液基因表达与单核苷酸多态性（SNPs）的肌萎缩侧索硬化（ALS）结局的孟德尔随机化分析结果。表S5：不同筛选标准下，大脑基因表达与单核苷酸多态性（SNPs）的肌萎缩侧索硬化（ALS）结局的孟德尔随机化分析结果。表S6：不同筛选标准下，脊髓基因表达与单核苷酸多态性（SNPs）的肌萎缩侧索硬化（ALS）结局的孟德尔随机化分析结果。表S7：与肌萎缩侧索硬化（ALS）相关的可药用基因。表S8：采用孟德尔随机化-埃格（MR-Egger）法和加权中位数法开展的敏感性分析结果。表S9：共定位分析结果。表S10：支持与肌萎缩侧索硬化（ALS）风险显著相关的可药用基因表达的瓦尔德比率（Wald ratio）法分析结果。表S11：采用逆方差加权（IVW）法或瓦尔德比率（Wald ratio）法进行的血液TBK1基因全表型组孟德尔随机化分析结果。